• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    implantable prosthesis. the present invention relates to an implantable prosthesis and a housing for an implantable prosthesis and methods for making them, in particular, a lightweight implantable prosthesis containing a biocompatible pad that is suitable for use as a breast implant.
    公开号:BR102012018848B1
    申请号:R102012018848-1
    申请日:2012-07-27
    公开日:2020-09-01
    发明作者:Ajay D. Padsalgikar
    申请人:Aortech International Plc；
    IPC主号:
    专利说明:

    FIELD
    [001] The present invention relates to an implantable prosthesis and a housing for an implantable prosthesis and methods for making them, in particular, a lightweight implantable prosthesis containing a biocompatible filler that is suitable for use as an implant mammary. BACKGROUND
    [002] Reconstructive and cosmetic surgery is now common practice. Specifically, cosmetic breast surgery has been developed to allow the reconstruction of a woman's breast that has been affected by procedures, such as mastectomy. Cosmetic breast surgery has also become available to correct the appearance of a woman's breast, for example, by adding an implant to increase the size of the breast, to correct asymmetries, change the shape and correct deformities.
    [003] Generally, the implant is required to be able to provide a specific shape and to keep the shape for many years, preferably for the life of the woman in which the implant is installed to provide the need for additional invasive surgery. The implant is also required to have a specific feel, preferably to mimic the feel of a real breast. The implant must also be biodegradable, such that it is not ruined by interaction with the human body and it must be biocompatible so that the woman's health is not adversely affected by the implant under extreme circumstances, for example, implant is not toxic in case of implant leakage.
    [004] The standard implants used today comprise an external shell typically made of vulcanized silicone or polyurethane and an internal content typically formed of a silicone gel or saline solution. The specific weight of the commonly used filler materials is generally between 0.95 to 1.15g / cm3. An average implant can weigh between 50 and 1,000 grams or even more. The weight of the implant is an addition, which is not insignificant for a person.
    [005] Over time, breast implants are known to cause problems, mostly related to the weight of the implant, for example, ptosis (ie, sagging and deformity), atrophy of the breast tissue, prominence of the implant through the breast tissue, back pain, and stretch of the skin.
    [006] An attempt was made to use salt to create porosity in the silicone breast implant carcasses. The porosity that leads to a cellular structure of the carcass was created on the outside of the implant mainly to address problems with capsular contracture. This concept was used to offset the density differences between the implant and the breast tissue. Density differences lead to wrinkles and fold defect failures associated with implants filled with saline. SUMMARY
    [007] It has been found that using the porosity inside instead of outside the carcass and using a thick layer of the porous structure can lead to an effective weight reduction of the implants. The "foam" housing can then be filled with the bio-compatible filler as normal.
    [008] In one aspect, an implantable prosthesis is provided that comprises: (i) an external housing with an inner surface and an outer surface, the outer surface is adapted to make contact with the tissue in the body; (ii) a biocompatible filling layer contained in the outer housing; (iii) a foamed inner layer with an inner shell and an outer shell that substantially prevents the foam pores from being filled with the biocompatible filling, the foamed inner layer being contained in the biocompatible filling layer; and (iv) repeating layers (ii) and (iii) one or more times if desired; and (v) a biocompatible filling contained in the inner shell of the inner layer with foam.
    [009] In another aspect, a housing for an implantable prosthesis is provided which comprises: (i) an external housing with an inner surface and an outer surface, the outer surface is adapted to make contact with the tissue in the body; (ii) a biocompatible filling layer contained in the outer housing; and (iii) a foamed inner layer provided with an inner shell and an outer shell that substantially prevents the foam pores from being filled with the biocompatible filler, the foamed inner layer being contained in the biocompatible filler layer; and (iv) repeat layers (ii) and (iii) one or more times if desired.
    [0010] In an additional aspect, a housing for an implantable prosthesis is provided which comprises: (i) an external housing with an inner surface and an outer surface, the outer surface is adapted to make contact with the tissue in the body; (ii) an inner foamed layer with an inner shell and an outer shell that substantially prevents the foam pores from being filled with biocompatible filling, the foamed inner layer being contained in the outer shell; and (iii) repeat layer (iii) one or more times if desired.
    [0011] Preferably, the implantable prosthesis is lightweight. The term "light weight" is used in the present context to refer to a prosthesis that achieves a weight reduction of up to 20% to 50% or more.
    [0012] Still in an additional aspect, a method is provided for making an implantable prosthesis defined above which comprises: (i) forming an inner housing; (ii) injecting a biocompatible filler into the inner housing; (iii) covering the inner housing with an inner layer with foam; (iv) foam the inner layer with an outer shell; (v) repeat steps (i) to (iv) one or more times if desired; (vi) lining the outer shell of the inner layer with foam with an outer shell; and (vii) injecting a biocompatible filler between the outer shell of the foamed inner layer and the outer shell.
    [0013] Each of the layers is preferably cured before coating another layer. The insertion is preferably by injection.
    [0014] The biocompatible filler is preferably a gel or a fluid and could be porous. DETAILED DESCRIPTION
    [0015] The present invention relates to an implantable prosthesis that includes (i) external housing, (ii) a biocompatible filling contained in the external housing, (iii) an internal foam layer with an inner housing and an outer housing that substantially prevents the foam pores from being filled with the biocompatible filler, (iv) repeating layers (i) to (iii) one or more times if desired and (v) a biocompatible filler contained in the foamed inner layer.
    [0016] The present invention also relates to a housing for an implantable prosthesis that includes (i) an external housing, (ii) a biocompatible filler contained in the external housing, (iii) an internal foam layer provided with an interior housing and an outer shell that substantially prevents the foam pores from being filled with the biocompatible filler and is able to accommodate a biocompatible filler and (iv) repeat layers (i) and (iii) one or more times if desired,
    [0017] The foamed inner layers result in the prosthesis and the housing that are lightweight. The filling could also be porous which would also reduce the weight of the prosthesis.
    [0018] The volume of the prosthesis and the space occupied by the filling can be calculated if it is assumed that the prosthesis is hemispheric, the volume occupied by the filling will be as follows:

    [0019] in which, R is the internal radius of the prosthesis. If the internal radius is reduced due to the porosity or foam formation introduced and the internal radius is taken as r, then the fraction of the volume occupied by the filling, f will be as follows:

    [0020] For a 9 cm prosthesis, a 1 cm porous structure in the prosthesis can lead to a smaller volume with more than 25% for the filling to occupy. With the "foamed" housing without adding significant weight to the prosthesis, a layer of foam can result in a significant reduction in the overall weight of the prosthesis. PROSTHESIS IMPLANTABLE
    [0021] The implantable prosthesis can be used in numerous locations on the body. Although the most common use is to recover and improve the normal body contour or increase, as well as reconstruct the female breast, it will be observed that the prosthesis can be implanted in other areas of the body, for example, to replace or enlarge the testicles, pectorals, a chin, cheeks, a potato, buttocks or other parts of a human or animal body, while exhibiting tactile properties similar to natural tissue. External, indoor and outdoor housings
    [0022] The outer, inner and outer housings can be composed of the same material or different materials, such as a material containing biocompatible silicon, for example, silicone or a polyurethane containing silicon.
    [0023] The term "silicone" as used herein refers to silicone or silicone based solids of varying hardness that includes elastomers, rubbers and resins. The hardness can be in the range of 10 to 90 Shore A. These polymers include silicon together with carbon, hydrogen and oxygen. Silicones are also known as polymerized siloxanes or polysiloxanes composed of units that have the formula (R) 2SiO in which R is an organic side chain that is not hydrogen. Representative examples are [SiO (CH3) 2] n (polydimethyl siloxane) and [SiO (C6H5) 2] n (polydiphenyl siloxane) in which n is an integer of 1 or greater. The compounds can be seen as a hybrid of both organic and inorganic compounds. The organic side chain confers hydrophobic properties while the linear chain -Si-O-Si-O- is purely inorganic. Examples of silicones or silicone-based materials include rubber, coatings, encapsulants and silicone sealants.
    [0024] Polyurethane is preferably bio-stable for use as a biomaterial in medical devices, articles or implants. Suitable bistable polyurethanes include polyurethanes, polyurethane ureas, in particular, polyurethanes, polyurethane ureas or silicon containing polycarbonates. Examples of polyurethane containing silicon, polyurethane ureas or polycarbonates include those described in W092 / 00338, WO98 / 13405, WO98 / 54242, WO99 / 03863, WO99 / 50327, WOOO / 64971 and W02007 / 112485, the total contents of which are incorporated into the present by reference. Polyurethanes, polyurethane ureas or polycarbonates usually contain a soft segment and a hard segment. The segments can be combined as copolymers or as mixtures. For example, polyurethanes with soft segments such as PTMO, polyethylene oxide, polypropylene oxide, polycarbonate, polyolefin, polysiloxane (eg polydimethyl siloxane) and other soft polyethylene segments made from larger homologous series of diols be used. Mixtures of any of the soft segments can be used as well. The soft segments can also have either final alcohol groups or final amine groups. The molecular weight of the soft segments can vary from about 500 to about 6000. It will be understood that the molecular weight values referred to herein are "average number molecular weights".
    [0025] Suitable soft polyether diol and diamine segments include those represented by the formula (I) A - [(CH2) m-O] n-A '(I)
    [0026] in which
    [0027] A and A 'are OH or NHR where R is H or optionally substituted C1-6 alkyl, more preferably, optionally substituted C1-4alkyl;
    [0028] m is an integer of 4 or more, preferably 4 to 18; and
    [0029] n is an integer from 2 to 50.
    [0030] The polyether diols of the formula (I) in which m is 4 to 10, such as poly-tetramethylene oxide (PTMO), polyhexanomethylene oxide (PHMO), poly-heptamethylene oxide, polyoctamethylene oxide (POMO) and polydecamethylene oxide (PDMO) are preferred. PHMO is particularly preferred.
    [0031] The preferred polyether molecular weight range is 200 to 5,000, more preferably 200 to 2,000.
    [0032] Suitable polycarbonate diols include alkylene polycarbonates) such as poly (hexamethylene carbonate) and decamethylene polycarbonate); polycarbonates prepared by reacting alkylene carbonate with alkanedioles, for example 1,4-butanediol, 1,10-decanediol (DD), 1,6-hexanediol (HD) and / or 2,2-diethyl 1,3-propanediol (DEPD ); and silicon-based polycarbonates prepared by reacting alkylene carbonate with 1,3-bis (4-hydroxybutyl) -1,1,3,3-tetramethyldisiloxane (BHTD) and / or alkanediols.
    [0033] It will be observed when both polyether macrodiol and polycarbonate are present, they can be in the form of a mixture or a copolymer. An example of a suitable copolymer is a macrodiol copoly (ether carbonate) represented by formula (II)

    [0034] in which
    [0035] Ri and Fb are the same or different and selected from an optionally substituted C1-6 alkylene, C2-6 alkanylene, C2-6 alkylene, arylene or a heterocyclic divalent radical; and
    [0036] p and q are integers from 1 to 20.
    [0037] Even though the compound of formula (II) above indicates blocks of carbonate and ether groups, it will be understood that they could also be randomly distributed in the main structure.
    [0038] Suitable polysiloxane diols or diamines are represented by formula (III):

    [0039] in which
    [0040] A and A 'are OH or NHR where R is H or optionally substituted C 1-6 alkyl, more preferably optionally substituted C 1-4 alkyl;
    [0041] R11, R12, Rn and Ru are independently selected from hydrogen or optionally substituted C1-6 alkyl;
    [0042] R15 and R16 are the same or different and selected from optionally substituted C1-6 alkylene, C2-6 alkanylene, C12-6 alkylene, arylene or a heterocyclic divalent radical; and
    [0043] p is an integer of 1 or greater.
    A preferred polysiloxane is a hydroxyl-terminated PDMS which is a compound of formula (III) in which A and A 'are hydroxyl, R11 to R14 are methyl and R15 and Rw are as defined above. Preferably R15 and R16 are the same or different and selected from propylene, butylene, pentylene, hexylene, ethoxypropyl (-CH2CH2OCH2CH2CH2-), propoxypropyl and butoxypropyl, more preferably ethoxypropyl. A particularly preferred polysiloxane is the Shin Etsu X-22-160AS product which has a molecular weight of 947.12 which is α-ω-bis (hydroxyethoxypropyl) polydimethyl siloxane.
    [0045] Other silicon-containing diols of formula (III) are 1,3-bis (4-hydroxybutyl) tetramethyl disiloxane (BHTD) (compound of formula (III) in which A and A 'are OH, Rn, R12, R13 and R14 are methyl, R15 and Rw are butyl and R17 is O), 1,4-bis (3-hydroxypropryl) tetramethyl disilylethylene (compound of formula (III) in which A and A 'are OH, Ri, R12, R13 and R14 are methyl, R15 and R16 are propryl and R17 is ethylene) and 1-4-bis (3-hydroxypropryl) tetramethyl disiloxane, more preferably BHTD.
    [0046] Polysiloxanes can be obtained as commercially available products, such as X-22-160AS from Shin Etsu in Japan or prepared according to known procedures. The preferred molecular weight range of the macrodiol polysiloxane is 200 to 6000, more preferably, 200 to 5,000.
    [0047] Other preferred polysiloxanes are polysiloxane macrodiamines which are polymers of formula (III) in which A is NH2, such as, for example, amino-terminated PDMS.
    [0048] Polycarbonates containing suitable silicon have the formula (IV):

    [0049] in which
    [0050] R11, R12, Rn, RU and R15 are defined in the formula (III) above;
    [0051] R16 is an optionally substituted C1-6 alkylene, C2-6 alkynylene, C2-6 alkynylene, arylene or a divalent heterocyclic radical;
    [0052] R17 is a divalent bonding group, preferably O, S or NRi8j
    [0053] R18 and R19 are the same or different and selected from hydrogen or optionally substituted C1-6 alkyl;
    [0054] A and A 'are as defined in formula (III) above;
    [0055] m, y and z are integers of 0 or more; and
    [0056] x is an integer of 0 or more.
    [0057] Preferably z is an integer from 0 to 50 and x is an integer from 1 to 50. Suitable values for m include 0 to 20, more preferably 0 to 10. Preferred values for y are 0 to 10, more preferably 0 to 2.
    [0058] A preferred silicon-containing polycarbonate is a compound of the formula (IV) in which A and A 'are hydroxyl.
    [0059] Particularly preferred polycarbonate diols containing silicon are compounds of the formula (IV) in which A and A 'are hydroxyl, R11, R12, Rn and Ru are methyl, Rw is ethyl, Rw is hexyl, R15 and R16 are propyl or R14 butyl and R17 is O or -CH2-CH2-, more preferably Rs and Rw are propyl when R17 is O and R15 and Rw are butyl when R17 is -CH2-CH2-. The preferred molecular weight range of silicon-based macrodiol polycarbonate is 400 to 5,000, more preferably 400 to 2,000.
    [0060] Preferably, the hard segment is formed of a diisocyanate and a chain extender.
    [0061] The diisocyanate can be represented by the formula OCN-R- NCO, where -R- can be aliphatic, aromatic, cycloalipathic portions or a mixture of aliphatic and aromatic portions. Examples of diisocyanates include 4,4'-diphenylmethane diisocyanate (MDI), methylene-cyclohexyl diisocyanate (H12 MDI), tetramethylene diisocyanate, hexamethylene diisocyanate, di- trimethyhexamethylene isocyanate, tetramethylxylylene diisocyanate, as p-tetramethylxylene diisocyanate (p-TMXDI) or m-tetramethylxylene diisocyanate (m-TMXDI), 4,4'-dicyclo diisocyanate -hexylmethane, dimer acid diisocyanate, isophorone diisocyanate (IPDI), metaxylene diisocyanate, diethylbenzene diisocyanate, decamethylene 1,10-diisocyanate, 1,2-diisocyanate of cyclohexylene, trans-cyclohexylene 1,4-diisocyanate (CHDI), 2,4-toluene diisocyanate (2,4-TDI), 2,6-toluene diisocyanate, di xylene isocyanate, p-phenylene diisocyanate (p-PDI), m-phenylene diisocyanate (m-PDI), hexahydro-toylene diisocyanate (and isomers), 1,5-diisocyanate naphthalene (NDI), 1-methoxyphenyl 2,4-diisocyanate, 4,4'-bi diisocyanate phenylene, 3,3'-dimethoxy-4,4'-biphenyl diisocyanate or 1,6-diisocyanate-hexane (DICH), isomers or mixtures thereof. Preferably, the diisocyanate is MDI.
    [0062] The term "chain extender" in the present context means any chain extender that is capable of reacting with a diisocyanate group. The chain extender generally has a molecular weight range of 500 or less, preferably 15 to 500, more preferably 60 to 450 and can be selected from diol or diamine chain extenders.
    [0063] Examples of diol chain extenders include C1-12 alkaline diols such as 1,4-butanediol (BDO), 1,6-hexanediol, 1,8-octanediol, 1,9-nonanediol, 1, 10-decanediol and 1,12-dodecanediol; cyclic diols, such as 1,4-cyclohexanediol, 1,4-cyclohexanedimethanol, 1,4-bis (2-hydroxyethoxy) benzene and p-xylene glycol; and silicon-containing diols such as 1,3-bis (4-hydroxybutyl) tetramethyldisiloxane and 1,3-bis (6-hydroxyethoxypropyl) tetramethyldisiloxane.
    [0064] Preferably, the diol chain extender is BDO.
    [0065] The diol chain extender may also contain silicon. Suitable diol chain extenders containing silicon include those of formula (V)

    [0066] in which
    [0067] Ri, Fb, Rs and R4 are the same or different and selected from H and an optionally substituted C1-6 alkyl;
    [0068] Rs and Re are the same or different and selected from optionally substituted C1-6 alkylene, C2-6 alkanylene, C12-6 alkylene, arylene and a heterocyclic divalent radical;
    [0069] R7 is a divalent bonding group, preferably O; and
    [0070] n is 0 or greater, preferably 2 or less.
    Suitable diamine chain extenders include C1-12 alkane diamines such as 1,2-ethylenediamine, 1,3-propanediamine, 1,4-butanediamine and 1,6-hexanediamine; and silicon-containing diamines, such as 1,3-bis (3-aminopropryl) tetramethyl disiloxane and 1,3-bis (4-aminobutyl) tetramethyldisiloxane.
    [0072] The diamine chain extender may also contain silicon. diamine chain extenders that contain suitable silicon include those of formula (VI)

    [0073] in which
    [0074] R is hydrogen or an optionally substituted C1-6 alkyl;
    [0075] R-i, R2, R3 and R4 are the same or different and selected from optionally substituted hydrogen and C1-6 alkyl;
    [0076] Rs and Re are the same or different and selected from optionally substituted C1-6 alkylene, C2-6 alkanylene, C12-6 alkylene, arylene and a heterocyclic divalent radical;
    [0077] R7 is a divalent bonding group, preferably O; and
    [0078] n is 0 or greater, preferably 2 or less.
    [0079] that the contents of the prosthesis leak. Optionally, the prosthesis can be supplied in various formats, for example, rounded, oval, anatomical, personalized or other and the external housing can be softened or textured with various patterns.
    [0080] The inner and outer housings house the inner layer with foam and substantially prevent the foam pores from being filled with the biocompatible filler. INTERNAL LAYER WITH FOAM
    [0081] The foamed inner layer is preferably a low density foam with open cell and can be composed of the same materials as described above for the outer, inner and outer housings. These materials can be made porous using any suitable known technique, such as the use of a blowing agent, for example, water or alcohol that produces hydrogen and the hydrogen is trapped by crosslinking the material containing bio-compatible silicon. Examples of suitable low density silicone foams are disclosed in US 4,767,794, the total contents of which are incorporated herein by reference.
    [0082] More than one foamed inner layer is advantageously present to result in a significant reduction in the overall weight of the prosthesis. The foamed inner layer is located between the inner and outer housings. BIOCOMPATIBLE FILLING
    [0083] The biocompatible filler can be a gel or a saline solution or a combination of both. When the filler is a gel it is typically a silicone gel that includes the bistable silicon containing gels described in W02006 / 034547 or W02007 / 121513.
    [0084] The filling is contained in the inner housing of the inner layer with foam. The inner shell ensures that there is substantially no migration of the filler to the inner foam layer (s) and the outer shell also ensures that there is no migration of the filler into the body. The migration of the filling to the body is a matter of concern in the use of such a prosthesis.
    [0085] The filling can take on a porous structure using a similar method as described with respect to the foamed inner layer above. This can lead to an even greater reduction in the weight of the prosthesis. METHOD
    [0086] The implantable prosthesis of the present invention can be made by foaming the inner housing using, for example, a mold, such as a mandrel. The biocompatible filling is then injected into the inner housing. The inner housing is then coated with an inner foam layer which is then covered with an outer housing. These steps can be repeated one or more times if desired. The outer shell of the foamed inner layer is then coated with an outer shell followed by the injection of a biocompatible filler between the outer shell of the foamed inner layer and the outer shell. It is important to ensure that the individual layers are cured before coating the subsequent layers. Curing can be achieved by allowing each layer to dry at room temperature or higher, for example, up to 160 ° C. When the foamed inner layer is coated, porosity is achieved by using a blowing agent as described above and then curing the layer.
    [0087] An exemplary embodiment of the invention will be described with reference to the following non-limiting drawings and / or example. BRIEF DESCRIPTION OF THE DRAWINGS
    [0088] Figure 1 is a cross-sectional drawing of an implantable prosthesis according to an exemplary embodiment of the present invention.
    [0089] In an exemplary embodiment of the invention, as shown in figure 1, an implantable prosthesis 2 includes an external housing 4 that can be composed of a material containing silicon, such as silicone or a polyurethane containing silicon. There is one or more layer (s) of biocompatible filler (s) 6 that is (are) typically a gel or saline solution contained in the outer shell 4. There is one or more inner layer (s) with foam 8 contained ( s) in the biocompatible filling layer (s). The biocompatible filler layer (s) 6 have (have) inner carcasses 10 and outer carcasses 12 which can be composed of the same materials as the outer carcass 4, thereby substantially preventing the pores of the foam are filled with the biocompatible filling. The foamed inner layer (s) 8 can be composed of the same material as the outer shell that has been made porous through the use of a blowing agent, such as water or alcohol.
    [0090] The implantable prosthesis is filled with a biocompatible filling 14 which is typically a gel or saline solution. EXAMPLES
    [0091] An embodiment of the invention will now be described with reference to the following non-limiting example.
    [0092] The different mandrels were manufactured with different ratios in such a way that a breast implant with a layer could be made. Four different carcasses were made, between the first two carcasses there was a gap of ~ 0.5 cm and a silicone gel was injected which was subsequently cured. Between the second and third carcasses there was a gap of ~ 1cm and the silicone foam (as disclosed in US 4,767,794) was injected, which is foamed to a density of <0.1 g / cc. In the space between the third and fourth carcass, the same silicone gel was injected and cured. The layered breast implant had its weight reduced to less than 50% for a similar sized breast implant with a uniform gel filling.
    [0093] In the claims that follow and in the preceding description of the invention, except where the context requires otherwise, due to the express language or necessary implication, the word "understand" or variations such as "understand" or "understand" is used in an inclusive sense, that is, to specify the presence of the declared features, but not to avoid the presence or addition of additional features in various embodiments of the invention.
    [0094] The complete description of all patents, patent documents and publications cited herein are incorporated by reference as if they were individually incorporated. The detailed description and previous examples were given for clarity of understanding only. No unnecessary limitations should be understood from them. The invention is not limited to the exact details shown and described for obvious variations to one skilled in the art that will be included in the invention defined by the claims.
    权利要求:
    Claims (15)
    [0001]
    1. Implantable layered prosthesis having layers with different radii characterized by the fact that it comprises: (i) an outer shell (4) of a silicone or a polyurethane containing silicon having an inner surface and an outer surface, the outer surface adapted to make contact with the tissue in the body; (ii) a biocompatible silicone gel filling layer (6) contained within the outer housing; (iii) an inner layer with low density silicone foam (8) having an inner shell (10) and an outer shell (12) that substantially prevents the foam pores from being filled with the biocompatible silicone gel filler, inner layer with low density silicone foam being contained within the biocompatible silicone gel filling layer; (iv) a biocompatible silicone gel filling (14) contained within the inner shell (10) of the inner layer with low density silicone foam (8); and (v) at least a second layer with low density silicone foam (8) having an inner shell (10) and an outer shell (12) and positioned between layers of biocompatible silicone gel filler (6).
    [0002]
    2. Prosthesis, according to claim 1, characterized by the fact that the carcasses (10, 12) have a hardness in the range of 10 to 90 Shore A and comprise polymerized polysiloxanes or siloxanes composed of units having the formula (R ) 2SiO where R is an organic chain that is not hydrogen and that gives hydrophobic properties while the linear chain -Si-O-Si-O is purely inorganic.
    [0003]
    3. Prosthesis, according to claim 1, characterized by the fact that the housings (10, 12) have a hardness in the range of 10 to 90 Shore A and comprises a polyurethane having a soft segment and a hard segment, the soft segment comprising polysiloxane having a molecular range of 500 to 6000 and represented by formula III:
    [0004]
    4. Prosthesis according to claim 3, characterized by the fact that the polysiloxane is a PDMS terminated in hydroxyl which is a compound of formula (III) above in which A and A 'are hydroxies, R11 to R14 are methyl and R15 and R16 are the same or different and selected from propylene, butylene, pentylene, hexylene, ethoxypropyl (-CH2CH2OCH2CH2CH2-), propoxypropyl and butoxypropyl.
    [0005]
    5. Prosthesis, according to claim 3, characterized by the fact that other silicon-containing diols of formula (III) are 1,3-bis (4-hydroxybutyl) tetramethyl disiloxane (BHTD) (compound of formula (III) in which A and A are OH, R11, R12, R13eR14 are methyl, R15eR16 are butyl and R17 is O), 1,4-bis (3-25hydroxypropril) tetramethyl disilylethylene (compound of formula (III) in which A and A 'are OH , R1, R12, R13 and R14 are methyl, R15 and R16 are propyl and R17 is ethylene) and 1-4-bis (3-hydroxypropryl) tetramethyl disiloxane, or BHTD.
    [0006]
    6. Prosthesis, according to claim 3, characterized by the fact that the polysiloxane macrodiamines which are polymers of the formula (III) in which A is NH2, and PDMS terminated in amino.
    [0007]
    7. Prosthesis, according to claim 3, characterized by the fact that the soft segment is polycarbonate containing silicon having a molecular weight in the range of 400 to 5000 and having the formula (IV):
    [0008]
    8. Prosthesis according to any one of claims 3 to 7, characterized by the fact that diisocyanate is a chain extender.
    [0009]
    9. Prosthesis, according to claim 8, characterized by the fact that 0 diisocyanate is represented by the formula OCN-R- NCO, where -R- can be aliphatic, aromatic, cycloalipathic molecules or a mixture of aliphatics and aromatic and include 4,4'-diphenylmethane (MDI) diisocyanate, methylene bisocclohexyl diisocyanate (H12 MDI), tetramethylene diisocyanate, hexamethylene diisocyanate, trimethihexamethylene diisocyanate , tetramethylxylylene diisocyanate, p-tetramethylxylene diisocyanate (p-TMXDI) or m-tetramethylxylene diisocyanate (m-TMXDI), 4,4'-dicyclohexylmethane diisocyanate, diisocyanate dimer acid, isophorone diisocyanate (IPDI), metaxylene diisocyanate, diethylbenzene diisocyanate, decamethylene 1,10-diisocyanate, cyclohexylene 1,2-diisocyanate, Trans-cyclohexylene 1,4-diisocyanate (CHDI), 2,4-toluene diisocyanate (2,4-TDI), 2,6-toluene diisocyanate, xylene diisocyanate, diisocyanate p-phenylene (p-PDI), m-phenylene diisocyanate (m-PDI), hexahydrotoylene diisocyanate (and isomers), naphthalene 1,5-diisocyanate (NDI), 2,4-di -1-methoxyphenyl isocyanate, 4,4'-biphenylene diisocyanate, 3,3'-dimethoxy-4,4'-biphenyl diisocyanate or 1,6-diisocyanate-hexane (DICH), isomers or mixtures of them.
    [0010]
    10. Prosthesis according to claim 8 or 9, characterized by the fact that the extensor chain comprises any one or more of 1,4-butanediol (BDO), 1,6-hexanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,4-cyclohexanediol, 1,4-cyclohexanedimethanol, 1,4-bis (2-hydroxyethoxy) benzene and p-xylene glycol; and 1,3-bis (4-hydroxybutyl) tetramethyldisiloxane and 1,3-bis (6-hydroxyethoxypropyl) tetramethyldisiloxane, suitable silicon-containing diol chain extenders include those of formula (V)
    [0011]
    11. Prosthesis according to any one of the preceding claims, characterized by the fact that the foamed inner layer (8) is a porous foam of low open cell density of the same materials as those of the carcasses (10, 12).
    [0012]
    12. Method for making an implantable layered prosthesis (2) having layers with different radii characterized by the fact that it comprises: (i) forming an inner shell (10) of a silicone or a polyurethane containing silicon; (ii) injecting a biocompatible silicone gel filling (14) into the inner housing (10); (iii) cover the inner housing (10) with an inner layer of low density silicone foam; (iv) coating the inner layer with foam (8) with an outer shell (12) of silicone or a silicon-containing polyurethane, where the inner shell (10) and outer shell (12) substantially prevent the pores of the foam are filled with the filling; (v) coating the outer shell (12) of the inner layer with foam (8) with an outer shell (4) of a silicone or polyurethane containing silicon; and (vi) injecting a biocompatible silicone gel filler (6) between the outer shell (12) of the foamed inner layer (8) and the outer shell (4), in which the inner layer with low density silicone foam (8) is contained within a layer of the biocompatible silicone gel pad and defined by, at least once: (vii) coating the outer layer with a second layer of foam (8); (viii) covering the second layer of foam (8) with a second outer shell (4); (ix) cover the second outer shell (4) of the second foam layer (8) with a second outer shell (4); and (x) injecting a second bio-compatible silicone gel filler between the second outer shell (4) of the inner foam layer (8) and the second outer shell (4).
    [0013]
    13. Method according to claim 12, characterized by the fact that the materials used are established as defined in any of claims 2 to 11.
    [0014]
    14. Method according to claim 12 or 13, characterized in that it comprises curing each layer of foam before an additional layer.
    [0015]
    Method according to any one of claims 12 to 14, characterized in that it comprises forming subsequent layers in the preceding outer layer
    类似技术:
    公开号 | 公开日 | 专利标题
    BR102012018848B1|2020-09-01|IMPLANTABLE LAYER PROSTHESIS AND METHOD FOR MAKING IMPLANTABLE LAYER PROSTHESIS
    US10213293B2|2019-02-26|Lightweight breast implant material
    US4455691A|1984-06-26|Silicone gel filled prosthesis
    US4650487A|1987-03-17|Multi-lumen high profile mammary implant
    US4472226A|1984-09-18|Silicone gel filled prosthesis
    US4773909A|1988-09-27|Multi-lumen high profile mammary implant
    US9138310B2|2015-09-22|Soft prosthesis shell texturing method
    US5376117A|1994-12-27|Breast prostheses
    ES2831550T3|2021-06-08|Soft filled prosthesis wrap with differentiated attachment surfaces
    US9452043B2|2016-09-27|Lightweight implantable prosthetic device
    US20040148024A1|2004-07-29|Soft tissue implant
    KR101235282B1|2013-02-21|Silicon artificial breast implants with minimized stress concentration and manufacturing method
    BRPI0805495A2|2010-09-08|silicone implant with expandable and / or interactive compartments, whether or not lined with ricinus communis polyurethane foam and / or hydroxyapatite, with tabs or cords
    JP2009531474A|2009-09-03|Biologically stable polyurethane
    BR112019020550A2|2020-04-28|soft prosthetic implant comprising macrotexturization and manufacturing method
    KR101067483B1|2011-09-27|Silicone sponge bead having dual micro-pore structure and method of manufacturing the same
    BR102019007694A2|2019-10-22|Breast Implant Weight Reduction Using Chemically Produced Foam Filler
    JP6530441B2|2019-06-12|Join method
    KR101032776B1|2011-05-06|The silicone breast implant which has low outflow of low molecular weight silicone
    Abraham et al.2018|A review of materials used in maxillofacial prosthesis-part 2.
    KR102358961B1|2022-02-10|Integrated radial silicone cell-structured human body implant and manufacturing method thereof
    Carantino2015|Correlation between the used polymeric biomaterials, implant design and clinical performance of the mammary implants
    Yuzhelevskii1991|Elastic siloxane materials for endoprosthetic applications
    同族专利:
    公开号 | 公开日
    US20130190870A1|2013-07-25|
    JP2013031661A|2013-02-14|
    US8882832B2|2014-11-11|
    BR102012018848A2|2014-03-18|
    EP2550942A1|2013-01-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4298998A|1980-12-08|1981-11-10|Naficy Sadeque S|Breast prosthesis with biologically absorbable outer container|
    US4767794A|1987-10-26|1988-08-30|General Electric Company|Low density silicone foam|
    US5282856A|1987-12-22|1994-02-01|Ledergerber Walter J|Implantable prosthetic device|
    US4944750A|1988-10-12|1990-07-31|Cox-Uphoff International Reel|Composite shell material for prosthesis|
    WO1992000338A1|1990-06-26|1992-01-09|Commonwealth Scientific And Industrial Research Organisation|Polyurethane or polyurethane-urea elastomeric compositions|
    US5496370A|1992-03-13|1996-03-05|Robert S. Hamas|Gel-like prosthetic device|
    US5437824A|1993-12-23|1995-08-01|Moghan Medical Corp.|Method of forming a molded silicone foam implant having open-celled interstices|
    AUPO251096A0|1996-09-23|1996-10-17|Cardiac Crc Nominees Pty Limited|Polysiloxane-containing polyurethane elastomeric compositions|
    AUPO700297A0|1997-05-26|1997-06-19|Cardiac Crc Nominees Pty Limited|Silicon-based polycarbonates|
    AUPO787897A0|1997-07-14|1997-08-07|Cardiac Crc Nominees Pty Limited|Silicon-containing chain extenders|
    AUPP268898A0|1998-03-31|1998-04-23|Cardiac Crc Nominees Pty Limited|High modulus polyurethane compositions|
    AUPP991799A0|1999-04-23|1999-05-20|Cardiac Crc Nominees Pty Limited|Siloxane-containing polyurethane-urea compositions|
    EP1799739B1|2004-09-29|2014-02-12|Aortech International plc|Gels|
    DK1877002T3|2005-04-25|2013-05-27|G & G Biotechnology Ltd|LIGHT WEIGHT IMPLANT PORTABLE DEVICE|
    JP2009531474A|2006-03-31|2009-09-03|エイオーテクバイオマテリアルズプロプライアタリーリミティド|Biologically stable polyurethane|
    WO2007121513A1|2006-04-20|2007-11-01|Aortech Biomaterials Pty Ltd|Gels|
    TWM342043U|2008-05-27|2008-10-11|jun-kai Huang|Light-weight breast shaping device|
    US9724189B2|2009-07-17|2017-08-08|Peter Forsell|Breast implant system|
    US8882832B2|2011-07-29|2014-11-11|Aortech International Plc|Implantable prosthesis|US20120165934A1|2010-12-15|2012-06-28|Allergan, Inc.|Collapsible, form-stable, fillable breast prosthesis|
    US8882832B2|2011-07-29|2014-11-11|Aortech International Plc|Implantable prosthesis|
    US8808373B2|2012-06-13|2014-08-19|Elwha Llc|Breast implant with regionalized analyte sensors responsive to external power source|
    US8790400B2|2012-06-13|2014-07-29|Elwha Llc|Breast implant with covering and analyte sensors responsive to external power source|
    US9144489B2|2012-06-13|2015-09-29|Elwha Llc|Breast implant with covering, analyte sensors and internal power source|
    US9144488B2|2012-06-13|2015-09-29|Elwha Llc|Breast implant with analyte sensors responsive to external power source|
    US8795359B2|2012-06-13|2014-08-05|Elwha Llc|Breast implant with regionalized analyte sensors and internal power source|
    US9211185B2|2012-06-13|2015-12-15|Elwha Llc|Breast implant with analyte sensors and internal power source|
    WO2014099799A1|2012-12-17|2014-06-26|Fitzgerald Patrick J|Cranial base implant device|
    US9486309B2|2014-04-25|2016-11-08|Allergan, Inc.|Lighter weight implant|
    EP3197395A4|2014-10-06|2018-06-20|Mark A. Anton|Expanded polytetrafluoroethylene covered breast implants to minimize capsular reaction and infection while reducing palpability|
    GB201521474D0|2015-12-04|2016-01-20|Univ Manchester|Textured surfaces for implants|
    CA3023507A1|2016-05-11|2017-11-16|Establishment Labs S.A.|Medical implants and methods of preparation thereof|
    WO2018067433A1|2016-10-03|2018-04-12|Lifecell Corporation|Breast treatment device|
    US10893935B2|2018-04-17|2021-01-19|Biosense WebsterLtd.|Reducing breast implant weight using chemically produced foam filling|
    法律状态:
    2014-03-18| B03A| Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]|
    2018-12-11| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2020-06-23| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2020-06-23| B15K| Others concerning applications: alteration of classification|Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61F 2/12 , A61L 27/34 , A61L 27/56 Ipc: A61L 27/18 (2006.01), A61L 27/56 (2006.01), A61F 2 |
    2020-09-01| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/07/2012, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    US201161513211P| true| 2011-07-29|2011-07-29|
    US61/513,211|2011-07-29|
    [返回顶部]